Compare EPAM Systems Inc (EPAM) vs Pfizer Inc (PFE) Price & Performance

EPAM Systems trades at $97.43, up 4.68% today, but faces bearish technical signals with resistance at $99. The company delivered strong Q2 2026 earnings beats with EPS of $3.38 versus $3.16 expected, though revenue guidance was lowered due to slower North American growth. Valuation metrics appear attractive with P/E of 13.22 and P/S of 0.94, while profitability remains solid with 7.15% net margin.

Despite near-term headwinds, EPAM's partnership with OpenAI and strong AI-native revenue growth provide long-term catalysts. Risks include software services demand softness and competitive pressures. Analyst consensus remains bullish with $117.27 price target (20% upside), though investors should monitor execution against revised guidance.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.